The COVID-19 pandemic accentuated the need for safety organizations to advance their methods of adverse event data processing and analysis in the face of increasingly diverse reporting requirements in different regions. Post-pandemic it’s more important than ever to rapidly access and analyse AE information, gain meaningful data insights, and understand the impact on product safety processes.
Addressing these challenges, the ever-evolving E2B(R3) and IDMP standards are intended to capture detailed standardized AE and medicinal product data, enable communication and collaboration amongst safety professionals, and ultimately provide patients and consumers with greater protection.
In this webinar we will explore:
This webinar is applicable to: